Breaking News Instant updates and real-time market news.

2023-01-25 14:30:01 $ECON Economic Data / + 14:30 01/25/23 01/25 14:30 01/25/23 14:30	U.S. economic calendar Thursday U.S. economic calendar Thursday includes several interesting reports but none that will really impact the FOMC's decision in a week's time. Headlining is the Advance Q4 GDP report where analysts are forecasting a slowing to a 2.2% pace from the 3.2% in Q3. Analysts expect a 2.3% clip for real final sales. The chain price index should decelerate slightly to a 4.0% rate from 4.4% previously. Also slated Thursday are durable goods, jobless claims, new home sales, and the advance indicators. Friday's reports include income, consumption, and the FOMC's favorite PCE price index, along with the final consumer sentiment and inflation stats from the University of Michigan survey.

2023-01-25 14:30:01

$ECON

Economic Data

/ +

14:30

01/25/23

01/25

14:30

01/25/23

14:30

U.S. economic calendar Thursday

U.S. economic calendar Thursday includes several interesting reports but none that will really impact the FOMC's decision in a week's time. Headlining is the Advance Q4 GDP report where analysts are forecasting a slowing to a 2.2% pace from the 3.2% in Q3. Analysts expect a 2.3% clip for real final sales. The chain price index should decelerate slightly to a 4.0% rate from 4.4% previously. Also slated Thursday are durable goods, jobless claims, new home sales, and the advance indicators. Friday's reports include income, consumption, and the FOMC's favorite PCE price index, along with the final consumer sentiment and inflation stats from the University of Michigan survey.

OTHER BREAKING NEWS FROM THE FLY

Syndicate	Quoin Pharmaceuticals files to sell $10M of ordinary shares » 06:05 02/03/23 02/03 06:05 02/03/23 06:05 QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) Represented by American… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 12/13/22 Quoin announces dosing of first patient in trial in Netherton Syndrome 11/03/22 Quoin Pharmaceuticals announces updated Q3 conference call timing 10/18/22 Quoin announces plans to initiate second trial in Netherton syndrome patients 09/13/22 Quoin Pharmaceuticals establishes patient specific website for ongoing study QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 09/07/22 Alliance Global Partners Quoin Pharmaceuticals initiated with a Buy at Alliance Global Partners 08/19/22 JMP Securities Quoin Pharmaceuticals price target lowered to $15 from $100 at JMP Securities 08/19/22 Maxim Quoin Pharmaceuticals price target lowered to $10 from $25 at Maxim 05/06/22 Ladenburg Ladenburg starts Quoin Pharmaceuticals at Buy with $2 price target QNRX Quoin Pharmaceuticals $2.51 / +0.19 (+8.19%) 11/10/22 Quoin Pharmaceuticals reports Q3 ADS (94c) vs ($5.84) last year 08/18/22 Quoin Pharmaceuticals reports Q2 EPS ($3.24) vs. ($18.05) last year
Downgrade	Hexcel downgraded to Neutral from Buy at BofA » 06:05 02/03/23 02/03 06:05 02/03/23 06:05 HXL Hexcel $71.23 / +0.03 (+0.04%) BofA analyst Ronald… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HXL Hexcel $71.23 / +0.03 (+0.04%) 10/25/22 Coinbase launches USDC institutional rewards program with MakerDAO 10/24/22 Hexcel did not repurchase any common stock during Q3 HXL Hexcel $71.23 / +0.03 (+0.04%) 01/30/23 Jefferies Hexcel price target raised to $70 from $60 at Jefferies 01/30/23 Wells Fargo Hexcel price target raised to $70 from $60 at Wells Fargo 01/27/23 Truist Hexcel price target raised to $59 from $53 at Truist 01/09/23 Truist Hexcel price target raised to $53 from $52 at Truist HXL Hexcel $71.23 / +0.03 (+0.04%) 01/25/23 Hexcel sees FY23 EPS $1.70-$1.90, consensus $1.82 01/25/23 Hexcel reports Q4 EPS 40c, consensus 32c 10/24/22 Hexcel narrows FY22 adjusted EPS view to $1.12-$1.24 from $1.00-$1.24 10/24/22 Hexcel reports Q3 adjusted EPS 33c, consensus 33c HXL Hexcel $71.23 / +0.03 (+0.04%) 01/25/23 Fly Intel: After-Hours Movers 02/15/23 44th Annual Aerospace/Defense & Industrials Conference
Downgrade	Camden Property downgraded on 'market drag' at Piper Sandler » 06:04 02/03/23 02/03 06:04 02/03/23 06:04 CPT Camden Property $126.29 / +2.55 (+2.06%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events CPT Camden Property $126.29 / +2.55 (+2.06%) 10/10/22 Camden Property estimates $1.0M in expenses related to Hurricane Ian 09/30/22 Camden Property says early reports indicate minor damage from Hurricane Ian 09/30/22 Camden Property provides update on Hurricane Ian CPT Camden Property $126.29 / +2.55 (+2.06%) 02/02/23 Piper Sandler Camden Property downgraded to Neutral from Overweight at Piper Sandler 01/10/23 Mizuho Camden Property upgraded to Buy from Neutral at Mizuho 01/04/23 Deutsche Bank Camden Property price target lowered to $140 from $153 at Deutsche Bank 12/15/22 UBS Camden Property initiated with a Buy at UBS CPT Camden Property $126.29 / +2.55 (+2.06%) 02/02/23 Camden Property sees Q1 FFO $1.63-$1.67, consensus $1.75 02/02/23 Camden Property sees FY23 FFO $6.70-$7.00, consensus $7.17 02/02/23 Camden Property reports Q4 FFO $1.74, consensus $1.74 10/27/22 Camden Property see FY22 FFO $6.57-$6.61, consensus $6.63 08 Apr 03/08/23 Miami Property Tour 11:00 Today Camden Property - CPT
Downgrade	Ford downgraded to Sell from Hold at Deutsche Bank » 06:04 02/03/23 02/03 06:04 02/03/23 06:04 F Ford $14.34 / +0.535 (+3.88%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford sees FY23 capital expenditures $8B-$9B 02/02/23 Ford down 6% after Q4 earnings report 02/02/23 Ford declares regular Q1 dividend of 15c, supplemental dividend of 65c 02/02/23 Ford reports January U.S. sales up 2% to 146,356 vehicles F Ford $14.34 / +0.535 (+3.88%) 01/25/23 JPMorgan Ford price target lowered to $15 from $16 at JPMorgan 01/11/23 Goldman Sachs Goldman continues to prefer Tesla and GM among automakers 12/21/22 Morgan Stanley Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley 12/05/22 Jefferies Fox Factory price target raised to $135 from $120 at Jefferies F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford sees FY23 adjusted EBIT of $9B-$11B 02/02/23 Ford reports Q4 adjusted EPS 51c, consensus 62c 02/02/23 Notable companies reporting after market close 10/26/22 Ford reports Q3 adjusted EPS 39c, consensus 27c F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford's Jan. U.S. sales increased 2% y/y, saw 'record' EV sales, Bloomberg says 01/24/23 Ford in discussions to sell German factory to BYD, WSJ reports 01/23/23 Union says Ford to slash up to 3,200 European jobs, Reuters reports 01/23/23 Ford planning massive layoffs overseas in favor of EV development, Electrek says F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Fly Intel: After-Hours Movers 01/30/23 What You Missed On Wall Street On Monday 01/30/23 What You Missed On Wall Street This Morning 01/30/23 Here's what Wall St. experts are saying about these automakers ahead of earnings F Ford $14.34 / +0.535 (+3.88%) 02/02/23 Ford options imply 5.2% move in share price post-earnings 01/17/23 Ford put volume heavy and directionally bearish 12/30/22 Notable open interest changes for December 30th 12/19/22 Unusually active option classes on open December 19th
Initiation	Herbalife Nutrition initiated with an Underperform at BofA » 06:03 02/03/23 02/03 06:03 02/03/23 06:03 HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) BofA analyst Anna Liznul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/06/22 Herbalife Nutrition falls -19.5% 12/06/22 Herbalife Nutrition falls -16.6% 12/06/22 Herbalife Nutrition falls -15.0% 12/05/22 Herbalife Nutrition falls 10% to $15.70 after offering $250M in convertible debt HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 11/01/22 B. Riley Herbalife Nutrition price target lowered to $31 from $38 at B. Riley 11/01/22 Citi Herbalife Nutrition price target lowered to $26 from $30 at Citi 10/05/22 Citi Herbalife Nutrition price target lowered to $30 from $36 at Citi 08/03/22 B. Riley Herbalife Nutrition price target lowered to $38 from $41 at B. Riley HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 10/31/22 Herbalife Nutrition reports Q3 EPS 91c, consensus 74c HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/06/22 What You Missed On Wall Street On Tuesday 12/06/22 What You Missed On Wall Street This Morning 12/06/22 Fly Intel: Pre-market Movers 12/05/22 Fly Intel: After-Hours Movers 03/21/23 6th Annual Consumer Growth Conference 02/14/23 Herbalife Nutrition - HLF HLF Herbalife Nutrition $18.25 / -0.325 (-1.75%) 12/23/22 Herbalife put volume heavy and directionally bearish 10/31/22 Herbalife options imply 8.4% move in share price post-earnings
Hot Stocks	Vyant Bio announces reduction in force and other measures to preserve cash » 06:03 02/03/23 02/03 06:03 02/03/23 06:03 VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) Vyant Bio announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 01/04/23 Vyant Bio engages LifeSci Capital to explore strategic alternatives 11/16/22 Vyant Bio regains compliance with Nasdaq minimum bid requirement 11/07/22 Vyant Bio teams up with IRSF to host local viewing party 11/03/22 Vyant Bio sells vivoPharm subsidiary to Reaction for $5.5M VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 10/04/22 Ascendiant Vyant Bio initiated with a Buy at Ascendiant VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 11/15/22 Vyant Bio reports Q3 EPS (59c) vs (77c) last year 08/22/22 Vyant Bio reports Q2 EPS (20c) vs (14c) last year VYNT Vyant Bio $1.02 / +0.0699 (+7.36%) 01/05/23 Fly Intel: Pre-market Movers
Recommendations	Alphabet price target raised to $155 from $130 at Oppenheimer » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 GOOG Alphabet $108.77 / +7.375 (+7.27%) Oppenheimer analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet says started bringing revenue sharing to YouTube Shorts 02/02/23 Alphabet reports Q4 Google Cloud revenue $7.3B vs. $5.54B last year 02/02/23 Alphabet taking actions to optimize global office space 02/01/23 'Tomb Raider Reloaded' coming to Google Play, iOS, Netflix on February 14 GOOG Alphabet $108.77 / +7.375 (+7.27%) 04:30 Today Piper Sandler Alphabet price target lowered to $120 from $122 at Piper Sandler 02/02/23 Morgan Stanley Meta Platforms price target raised to $190 from $130 at Morgan Stanley 01/31/23 BofA Alphabet price target raised to $119 at BofA ahead of earnings 01/30/23 KeyBanc Trade Desk price target lowered to $55 from $56 at KeyBanc GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet reports Q4 EPS $1.05, consensus $1.18 02/02/23 Notable companies reporting after market close 10/25/22 Alphabet reports Q3 EPS $1.06, consensus $1.25 10/25/22 Notable companies reporting after market close GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Democratic senator joins calls to ban TikTok, WSJ reports 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Google testing ChatGPT-like products, including 'Apprentice Bard,' CNBC reports 01/31/23 Reels sharing revenue with creators hotly debated within Meta, Information says GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 What Wall Street is saying about Alphabet ahead of earnings 02/01/23 #SocialStocks: Meta circumvents FTC challenge and will acquire Within Unlimited GOOG Alphabet $108.77 / +7.375 (+7.27%) 02/02/23 Alphabet options imply 5.9% move in share price post-earnings 01/20/23 Unusually active option classes on open January 20th 12/14/22 Alphabet put buyer realizes 126% same-day gains 11/02/22 Alphabet put buyer realizes 98% same-day gains
Earnings	Cigna reports Q4 adjusted EPS $4.96, consensus $4.86 » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 CI Cigna $301.39 / -11.73 (-3.75%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CI Cigna $301.39 / -11.73 (-3.75%) 02/02/23 Managed care stocks pressured after CMS' preliminary Medicare Advantage rates 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices 12/06/22 Walmart to pay $500,000 over workers' compensation prescription procedures 11/07/22 WBA to invest $3.5B to support VillageMD acquisition of Summit Healt-CityMD CI Cigna $301.39 / -11.73 (-3.75%) 01/31/23 JPMorgan Medicare Advantage final rule more favorable than feared, says JPMorgan 01/03/23 Wells Fargo Wells Fargo downgrades Cigna to Equal Weight, lowers price target to $355 01/03/23 Wells Fargo Cigna downgraded to Equal Weight from Overweight at Wells Fargo 11/23/22 Morgan Stanley Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley CI Cigna $301.39 / -11.73 (-3.75%) 02/02/23 Notable companies reporting before tomorrow's open 02/02/23 Notable companies reporting before tomorrow's open 11/03/22 Cigna raises FY22 adjusted EPS view to at least $23.10 from at least $22.90 11/03/22 Cigna reports Q3 adjusted EPS $6.04, consensus $5.71 CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 Cigna sues CVS Health, Amy Bricker for violating noncompete, Bloomberg Law says 11/29/22 Managed care company returns will be tough to keep replicating, WSJ says 11/07/22 Walgreens-backed VillageMD close to $9B deal with Summit, WSJ reports 08/18/22 White House plans for end of COVID-19 vaccine coverage, WSJ reports CI Cigna $301.39 / -11.73 (-3.75%) 01/27/23 What You Missed On Wall Street This Morning 11/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Fly Intel: Pre-market Movers 08:30 Today Cigna - CI CI Cigna $301.39 / -11.73 (-3.75%) 01/13/23 Early notable gainers among liquid option names on January 13th
Recommendations	Paylocity price target raised to $297 from $276 at Piper Sandler » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 PCTY Paylocity $226.21 / +6.61 (+3.01%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly Events PCTY Paylocity $226.21 / +6.61 (+3.01%) 11/04/22 KeyBanc Paylocity price target lowered to $295 from $310 at KeyBanc 10/28/22 DA Davidson Paylocity cut to Neutral at DA Davidson on valuation, expectations for softer Q1 10/28/22 DA Davidson Paylocity downgraded to Neutral from Buy at DA Davidson 10/24/22 Needham Needham adds Five9 to Conviction List, removes Paylocity PCTY Paylocity $226.21 / +6.61 (+3.01%) 02/02/23 Paylocity sees FY23 revenue $1.156B-$1.161B, consensus $1.12B 02/02/23 Paylocity sees Q3 revenue $330.5M-$334.5M, consensus $318.65M 02/02/23 Paylocity reports Q2 non-GAAP EPS $1.12, consensus 73c 11/03/22 Paylocity sees Q2 revenue $257M-$261M, consensus $254.69M PCTY Paylocity $226.21 / +6.61 (+3.01%) 02/02/23 Fly Intel: After-Hours Movers 03/06/23 Technology Conference
Earnings	Johnson Outdoors reports Q1 EPS 57c vs. $1.07 a year ago » 06:02 02/03/23 02/03 06:02 02/03/23 06:02 JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) Reports Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Events JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) 09/29/22 Johnson Outdoors raises quarterly cash dividend to 31c per share JOUT Johnson Outdoors $71.37 / +2.04 (+2.94%) 12/09/22 Johnson Outdoors reports Q4 EPS 95c vs. 68c a year ago 11:00 Today Johnson Outdoors - JOUT 03/01/23 Johnson Outdoors, Inc.

Downgrade	Direct Line Insurance downgraded to Underweight from Equal Weight at Barclays » 06:00 02/03/23 02/03 06:00 02/03/23 06:00 DIISY Direct Line Insurance $9.10 / +0.47 (+5.45%) Barclays analyst Ivan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research DIISY Direct Line Insurance $9.10 / +0.47 (+5.45%) 01/30/23 Berenberg Direct Line Insurance price target lowered to 159 GBp from 160 GBp at Berenberg 01/25/23 Berenberg Direct Line Insurance downgraded to Hold from Buy at Berenberg 01/24/23 UBS Direct Line Insurance price target lowered to 190 GBp from 194 GBp at UBS 01/24/23 Citi Direct Line Insurance downgraded to Sell from Neutral at Citi
Hot Stocks	Creative Media & Community Trust acquires three multifamily assets » 05:59 02/03/23 02/03 05:59 02/03/23 05:59 CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) CMCT announced that it is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) 08/15/22 CMCT signs long-term lease with O'Gara Coach for Beverly Hills showroom CMCT Creative Media & Community Trust $5.36 / -0.03 (-0.56%) 09/29/22 Edward Jones CIM Commercial Trust initiated with a Buy at Edward Jones
Recommendations	MAA price target raised to $190 from $180 at JMP Securities » 05:58 02/03/23 02/03 05:58 02/03/23 05:58 MAA MAA $173.90 / +5.49 (+3.26%) JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MAA MAA $173.90 / +5.49 (+3.26%) 12/13/22 MAA raises quarterly dividend 12% to $1.40 per share 10/19/22 MAA announces planned retirement of COO Thomas Grimes MAA MAA $173.90 / +5.49 (+3.26%) 01/17/23 Truist MAA downgraded to Hold from Buy at Truist 01/11/23 BTIG MAA price target lowered to $175 from $225 at BTIG 01/09/23 Credit Suisse MAA downgraded to Neutral from Outperform at Credit Suisse 01/03/23 Jefferies Independence Realty Trust downgraded at Jefferies on macro concerns MAA MAA $173.90 / +5.49 (+3.26%) 02/01/23 MAA sees Q1 core FFO $2.14-$2.30, consensus $2.25 02/01/23 MAA sees FY23 core FFO $8.88-$9.28, consensus $9.16 02/01/23 MAA reports Q4 core FFO $2.32, consensus $2.28 10/26/22 MAA sees Q4 core FFO $2.19-$2.35, consensus $2.20
Upgrade	H.B. Fuller upgraded to Buy from Neutral at Citi » 05:58 02/03/23 02/03 05:58 02/03/23 05:58 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) Citi analyst Eric Petrie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 09/26/22 H.B. Fuller names Celeste Mastin as new CEO 09/21/22 H.B. Fuller narrows FY22 adjusted EBITDA view to $540M-$550M from $530M-$550M FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/23/23 Citi H.B. Fuller price target raised to $72 from $65 at Citi 01/20/23 Deutsche Bank H.B. Fuller price target raised to $78 from $72 at Deutsche Bank 01/20/23 Baird H.B. Fuller price target lowered to $80 from $85 at Baird 10/13/22 Baird H.B. Fuller margins biased higher despite macro evironment, says Baird FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 H.B. Fuller sees FY23 adjusted EPS $4.15-$4.55, consensus $4.63 01/18/23 H.B. Fuller reports Q4 adjusted EPS $1.04, consensus $1.24 09/21/22 H.B. Fuller sees Q4EPS $1.15-$1.30, consensus $1.28 09/21/22 H.B. Fuller reports Q3 EPS $1.06, consensus $1.04 FUL H.B. Fuller $73.22 / +2.91 (+4.14%) 01/18/23 Fly Intel: After-Hours Movers 09/22/22 What You Missed On Wall Street This Morning 09/22/22 Fly Intel: Pre-market Movers 09/21/22 Fly Intel: After-Hours Movers
Hot Stocks	XPeng launches G9 SUV, P7 sports sedan in European markets » 05:57 02/03/23 02/03 05:57 02/03/23 05:57 XPEV XPeng $11.05 / -0.09 (-0.81%) XPeng launched its two… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options XPEV XPeng $11.05 / -0.09 (-0.81%) 02/01/23 XPeng delivers 5,218 Smart EVs in January 01/06/23 XPeng falls -15.8% 01/06/23 XPeng falls -16.1% 01/06/23 XPeng falls -11.3% XPEV XPeng $11.05 / -0.09 (-0.81%) 01/11/23 JPMorgan XPeng downgraded to Neutral from Overweight at JPMorgan 01/06/23 BofA XPeng downgraded to Neutral at BofA after Tesla price cuts 01/06/23 BofA XPeng downgraded to Neutral from Buy at BofA 01/04/23 Wedbush Demand issues, Twitter focus creates 'perfect storm' for Tesla, says Wedbush XPEV XPeng $11.05 / -0.09 (-0.81%) 11/30/22 XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B 11/30/22 XPeng reports Q3 EPS (36c), consensus (36c) 08/23/22 XPeng sees Q3 revenue RMB6.8B-RMB7.2B, up 18.9%-25.9% from last year 08/23/22 XPeng reports Q2 no-GAAP EPS (43c), consensus ($2.61) XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 XPeng follows Tesla with price cuts in China, Reuters reports 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports XPEV XPeng $11.05 / -0.09 (-0.81%) 01/17/23 What You Missed On Wall Street On Tuesday 01/17/23 What You Missed On Wall Street This Morning 01/17/23 What You Missed This Week in EVs and Clean Energy 01/17/23 Fly Intel: Pre-market Movers XPEV XPeng $11.05 / -0.09 (-0.81%) 01/30/23 XPeng call volume above normal and directionally bullish 01/27/23 XPeng call volume above normal and directionally bullish 01/24/23 XPeng call volume above normal and directionally bullish 01/23/23 XPeng call volume above normal and directionally bullish
Downgrade	Repare Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 01/19/23 Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/17/22 H.C. Wainwright Repare Therapeutics price target lowered to $25 from $38 at H.C. Wainwright 06/06/22 H.C. Wainwright Repare Therapeutics price target lowered to $38 from $54 at H.C. Wainwright 06/02/22 Piper Sandler Piper ups Repare Therapeutics target after 'great deal' with Roche 04/12/22 Stifel Stifel downgrades Repare Therapeutics after 'blow to synthetic lethality thesis' RPTX Repare Therapeutics $13.16 / +0.62 (+4.94%) 11/09/22 Repare Therapeutics reports Q3 EPS $1.71, consensus (89c)
General news	Energy Action: » 05:55 02/03/23 02/03 05:55 02/03/23 05:55 $ECON Economic Data / + Energy Action: Oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals On The Fly $ECON Economic Data / + $ECON Economic Data / + 01/30/23 Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says 01/22/23 Fed sets course for milder interest-rate rise next month, WSJ says 11/04/22 Fed's Evans says smaller rate hikes make sense, Reuters reports 10/22/22 Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says $ECON Economic Data / + 02/01/23 What You Missed On Wall Street On Wednesday 01/24/23 What You Missed On Wall Street On Tuesday 01/18/23 What You Missed On Wall Street On Wednesday 12/15/22 What You Missed On Wall Street On Thursday
Upgrade	Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley » 05:54 02/03/23 02/03 05:54 02/03/23 05:54 NBIX Neurocrine $107.96 / -2.045 (-1.86%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NBIX Neurocrine $107.96 / -2.045 (-1.86%) 01/09/23 Xenon Pharmaceuticals outlines key milestone opportunities for 2023 01/09/23 Voyager, Neurocrine enter collaboration to advance multiple gene therapies 12/22/22 Neurocrine: FDA accepts sNDA for valbenazine 12/06/22 Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2 NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/13/22 RBC Capital Neurocrine CAH data appears pushed back, says RBC Capital 11/14/22 Evercore ISI Neurocrine downgraded to In Line from Outperform at Evercore ISI 11/02/22 BMO Capital Neurocrine price target raised to $101 from $78 at BMO Capital 11/02/22 Wells Fargo Neurocrine price target raised to $120 from $110 at Wells Fargo NBIX Neurocrine $107.96 / -2.045 (-1.86%) 11/01/22 Neurocrine reports Q3 non-GAAP EPS $1.08, consensus 79c 08/04/22 Neurocrine reports Q2 non-GAAP EPS 84c, consensus 15c NBIX Neurocrine $107.96 / -2.045 (-1.86%) 12/06/22 Fly Intel: After-Hours Movers 09/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/06/23 Biotech Ski Summit 02/06/23 Neurocrine - NBIX
Downgrade	Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 IMRX Immuneering $4.16 / +0.05 (+1.22%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/28/22 Immuneering doses first patient in Phase 1/2a trial of IMM-1-104 11/10/22 Immuneering presents preclinical data on its second program IMM-6-415 10/20/22 Immuneering names Leah Neufeld as Chief People Officer 09/30/22 Immuneering: FDA clears IND for Phase 1/2a clinical trial of IMM-1-104 IMRX Immuneering $4.16 / +0.05 (+1.22%) 12/20/22 Piper Sandler Piper recommends 'down market cap' biotech exposure for 2023 09/30/22 Piper Sandler Immuneering transitions to clinical stage with IND approval, says Piper Sandler 07/25/22 Piper Sandler Immuneering CFO departure not a 'red flag,' says Piper Sandler 07/08/22 Chardan Immuneering initiated with a Buy at Chardan IMRX Immuneering $4.16 / +0.05 (+1.22%) 11/10/22 Immuneering expects FY22 GAAP operating expenses $53M-$56M 11/10/22 Immuneering reports Q3 EPS (49c), consensus (49c)
Earnings	Sanofi sees 2023 business EPS up at low single digit rate at CER » 05:53 02/03/23 02/03 05:53 02/03/23 05:53 SNY Sanofi $47.22 / -1.505 (-3.09%) Sanofi expects 2023… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 05:52 Today Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names

Upgrade	Esperion upgraded to Equal Weight from Underweight at Morgan Stanley » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 ESPR Esperion $5.91 / -0.49 (-7.66%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ESPR Esperion $5.91 / -0.49 (-7.66%) 01/11/23 RFK Racing enters team-wide partnership with Esperion 12/07/22 Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL 11/16/22 Esperion promotes Ben Halladay to CFO role 08/26/22 Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force ESPR Esperion $5.91 / -0.49 (-7.66%) 12/07/22 H.C. Wainwright H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint 08/03/22 Credit Suisse Esperion downgraded to Underperform from Neutral at Credit Suisse 05/04/22 JPMorgan Esperion upgraded to Neutral on achievable estimates at JPMorgan 05/04/22 JPMorgan Esperion upgraded to Neutral from Underweight at JPMorgan ESPR Esperion $5.91 / -0.49 (-7.66%) 01/08/23 Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M 11/01/22 Esperion reports Q3 EPS (81c), consensus (92c) ESPR Esperion $5.91 / -0.49 (-7.66%) 12/09/22 Biotech Alert: Searches spiking for these stocks today 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ESPR Esperion $5.91 / -0.49 (-7.66%) 01/06/23 Esperion call volume above normal and directionally bullish 12/19/22 Esperion put volume heavy and directionally bearish 12/07/22 Unusually active option classes on open December 7th 11/17/22 Largest borrow rate increases among liquid names
Earnings	Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER » 05:52 02/03/23 02/03 05:52 02/03/23 05:52 SNY Sanofi $47.22 / -1.505 (-3.09%) IFRS EPS for Q4 was EUR… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization 01/27/23 Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent 01/25/23 Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial 01/25/23 Innate Pharma announces HSR clearance for Sanofi collaboration expansion SNY Sanofi $47.22 / -1.505 (-3.09%) 01/31/23 Berenberg Sanofi price target raised to EUR 100 from EUR 91 at Berenberg 12/21/22 Barclays Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays 12/16/22 Goldman Sachs Sanofi reinstated with a Buy at Goldman Sachs 12/15/22 Guggenheim Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential SNY Sanofi $47.22 / -1.505 (-3.09%) 10/28/22 Sanofi now sees 2022 business EPS growing 16% at CER 10/28/22 Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER SNY Sanofi $47.22 / -1.505 (-3.09%) 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 12/24/22 Pfizer, Moderna among vaccine makers to watch in 2023, Barron's says SNY Sanofi $47.22 / -1.505 (-3.09%) 12/21/22 Biotech Alert: Searches spiking for these stocks today 11/30/22 What You Missed On Wall Street On Wednesday 11/30/22 What You Missed On Wall Street This Morning 11/30/22 Fly Intel: Pre-market Movers 03/09/23 Biopharma/Biotech 02/22/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/24/23 Annual Meeting of AAAAI 2023 08:00 Today Sanofi - SNY SNY Sanofi $47.22 / -1.505 (-3.09%) 11/11/22 Sanofi put volume heavy and directionally bearish 10/11/22 Sanofi put volume heavy and directionally bearish 09/26/22 Largest borrow rate increases among liquid names
Upgrade	Erasca upgraded to Overweight from Equal Weight at Morgan Stanley » 05:51 02/03/23 02/03 05:51 02/03/23 05:51 ERAS Erasca $4.16 / +0.165 (+4.13%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Syndicate On The Fly ERAS Erasca $4.16 / +0.165 (+4.13%) 12/20/22 Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/13/22 Erasca announces FDA clearance of IND application for ERAS-3490 12/09/22 Erasca announces pricing of underwritten offering of common stock 12/09/22 Erasca, Novartis enter worldwide license agreement for naporafenib ERAS Erasca $4.16 / +0.165 (+4.13%) 11/09/22 Erasca reports Q3 EPS (29c), consensus (31c) 09 Dec ERAS Erasca $4.16 / +0.165 (+4.13%) 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning
Downgrade	Cyteir downgraded to Underweight from Equal Weight at Morgan Stanley » 05:50 02/03/23 02/03 05:50 02/03/23 05:50 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/19/23 Cyteir Therapeutics announces prioritization of CYT-0851 development 08/08/22 Cyteir Therapeutics expects cash to fund operations into second half of 2024 CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral at BofA after strategic prioritization 01/30/23 BofA Cyteir Therapeutics downgraded to Neutral from Buy at BofA 01/20/23 JPMorgan Cyteir Therapeutics downgraded to Neutral from Overweight at JPMorgan 09/09/22 Morgan Stanley Cyteir downgraded at Morgan Stanley with time needed for data CYT Cyteir Therapeutics $1.61 / +0.02 (+1.26%) 11/07/22 Cyteir Therapeutics reports Q3 EPS (31c), consensus (41c) 08/08/22 Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c)
Downgrade	Meta Platforms downgraded to Reduce from Hold at HSBC » 05:48 02/03/23 02/03 05:48 02/03/23 05:48 META Meta Platforms $188.78 / +35.675 (+23.30%) HSBC analyst Nicolas… HSBC analyst Nicolas Cote-Colisson downgraded Meta Platforms to Reduce from Hold with an unchanged price target of $110. The company's Q4 results showed higher engagement, but revenue was still down, the analyst tells investors in a research note. The firm says headwinds for the company include the macro environment, competition and regulation versus one "longer-term tailwind that is Meta's lead in Metaverse." The recent share rally leads HSBC to downgrade the shares to Reduce. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B 02/01/23 Meta says 2023 will be 'a year of efficiency' 02/01/23 Meta Platforms announces $40B increase in share repurchase authorization 02/01/23 Meta Platforms reports FoA and RL segment restructuring charges META Meta Platforms $188.78 / +35.675 (+23.30%) 05:13 Today DZ Bank Meta Platforms upgraded to Hold from Sell at DZ Bank 02/02/23 Deutsche Bank Meta Platforms price target raised to $200 from $125 at Deutsche Bank 02/02/23 RBC Capital Meta Platforms price target raised to $225 from $160 at RBC Capital 02/02/23 Needham Meta Platforms reported fundamentals still deteriorating, says Needham META Meta Platforms $188.78 / +35.675 (+23.30%) 02/01/23 Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B 02/01/23 Meta Platforms reports Q4 EPS $1.76, consensus $2.22 02/01/23 Notable companies reporting after market close 11/09/22 Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 FTC denies Meta request to bar Khan from antitrust case, Bloomberg says 02/01/23 GoodRx to pay $1.5M fine over sharing health data, Bloomberg Law reports 02/01/23 Meta wins approval over FTC to acquire Within Unlimited, Bloomberg says 02/01/23 Meta debates on whether to share Reel money with creators, Information reports META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers META Meta Platforms $188.78 / +35.675 (+23.30%) 02/02/23 Earnings season driving record option volume 02/02/23 Early notable gainers among liquid option names on February 2nd 02/02/23 Notable open interest changes for February 2nd 02/01/23 Meta Platforms (Facebook) options imply 8.9% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

AVTR
Today at 08:00

Avantor - AVTR Conference Calls
TWST
Today at 08:00

Twist Bioscience - TWST Conference Calls
SNY
Today at 08:00

Sanofi - SNY Conference Calls
Today at 08:30

Employment Situation: Average Workweek: January 2023 Government Event
Today at 08:30

Employment Situation: Private Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Manufacturing Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Participation Rate: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Non-Farm Payrolls M/M: January 2023 Government Event
Today at 08:30

Employment Situation: Average Hourly Earnings Y/Y: January 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	VERA X VERA Vera Therapeutics Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LIFC Priced at: $7.00 14.286M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ALGM X ALGM Allegro MicroSystems Block Trade Managers: Credit Suisse Priced at: $38.00 4.98M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GPCR X GPCR Structure Therapeutics IPO Managers: Jefferies, SVB Securities, Guggenheim & BMO Capital Priced at: $15.00 10.74M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ROIV X ROIV Roivant Sciences Secondary Managers: Goldman Sachs, SVB Securities, Cowen & Cantor Fitzgerald Priced at: $7.50 26.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AVTX X AVTX Avalo Therapeutics Spot Secondary Managers: SVB Securities & RBC Capital Priced at: $3.98 3.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDBL X EDBL Edible Garden Spot Secondary Managers: Maxim & Joseph Gunnar Priced at: $6.30 1.62M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	WULF X WULF TeraWulf Spot Secondary Managers: JonesResearch $1.03
Thurs	ASST X ASST Asset Entities IPO Managers: Boustead $5.00 1.5M Shares SODR X SODR Sondors IPO Managers: DA Davidson & Lake Street $8.00 - 10.00 2.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDXH X MDXH MDxHealth Secondary Managers: Cowen & William Blair, BTIG, KBCS $6.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CLLS X CLLS Cellectis Spot Secondary Managers: Jefferies & Barclays $3.26 22M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TWO X TWO Two Harbors Spot Secondary Managers: Goldman Sachs, JPMorgan & Citi, JMP Securities $17.80-18.00 10M Shares
Fri	No deals

View All Syndicate Announcements »

U.S. economic calendar Thursday

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access